Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN99993 | Evodiamine Evodiamine, a novel non-pungent vanilloid receptor agonist, which has the effects of anti-obese, analgesic, vasodilator, anti-oxidation, anti-inflammatory and anti-cancer. It prevents the accumulation of perivisceral fat and the body weight increase, blocks of the Ca2+ influx through receptor-mediated Ca2+ channels, inhibits NF-kB activation through suppression of IkB kinase activity. |
| CFN98204 | Cytochalasin D Cytochalasin D is an actin inhibitor, the removal of actin stress fibers is crucial for the chondrogenic differentiation. It may be an inhibitor of some fertilization processes such as sperm penetration or sperm head decondensation. Cytochalasin D inhibits CT26 tumor growth potentially through inhibition of cell proliferation, induction of cell apoptosis and suppression of tumor angiogenesis; it stimulates the expression of TF in B16 melanoma cells, activating both coagulation-dependent and -independent pathways via binding to FVIIa, eventually promoting lung metastasis. Cytochalasin D is also an inhibitor of microfilament-dependent phagocytosis, it (0.5 or 1.0 micrograms/ml) can inhibit intracellular multiplication of L. pneumophila in U937 monocytes. Cytochalasin D inhibits smooth muscle contraction by directly inhibiting contractile apparatus. |
| CFN98205 | 11-Hydroxytabersonine 11-Hydroxytabersonine has antitumor activety. |
| CFN99997 | Peiminine Peiminine has potent anti-inflammatory, anti-allergic, antitussive, and expectorant effects. It induces autophagic cell death thus represses colorectal carcinoma tumor growth. Peiminine can inhibit lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury, by reducing circulating IFN-γ levels and inhibiting signal transduction pathways involving TGF-β, CTGF, ERK1/2, NF-κB and FasL. |
| CFN98102 | Jujuboside B Jujuboside B has antitumor activity and the underlying mechanism via induction of apoptosis and autophagy. It reduces vascular tension endothelium-dependently by increasing Ca2+Influx and activating endothelial nitric oxide synthase, it has pharmacological effects on improving endothelial dysfunction and treating vascular diseases. |
